Biotechnology Contract Manufacturing Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Biotechnology Contract Manufacturing Market- (By Service (Manufacturing, Formulation and Fill-Finish, Packaging and Labeling, Other services), By Type (Biologic Drug Substance Manufacturing, Biologic Drug Product Manufacturing), By Scale of Operation (Commercial Operations, Clinical Operations), By Source (Mammalian Expression Systems, Non-Mammalian Expression Systems), By Molecule (Monoclonal Antibodies, Cell Therapy & Gene Therapy. Antibody-Drug Conjugates (ADCs), Vaccines, Therapeutic Peptides & Proteins, Other Molecule Types), By Therapeutic Area (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Neurology, Other Therapeutic Areas)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Biotechnology Contract Manufacturing Market is valued at USD 16.28 Bn in 2023 , and it is expected to reach USD 31.05 Bn by the year 2031, with a CAGR of 8.68% during a forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2067
Biotechnology contract manufacturing involves the delegation of biotechnological and pharmaceutical production processes to specialized third-party organizations known as Contract Manufacturing Organizations (CMOs). These entities offer comprehensive services to biotechnology and pharmaceutical companies, including the manufacturing of biopharmaceuticals, vaccines, gene therapies, and medical devices. By outsourcing these operations, biotechnology and pharmaceutical firms are able to concentrate on their core areas of expertise while optimizing internal resource allocation and enhancing operational efficiency.
The growth of the global biotechnology contract manufacturing market is primarily driven by access to advanced and capital-intensive technologies, increased operational flexibility, and the accelerated commercialization of innovative products. Technological advancements and continuous innovation in bioprocessing have further mitigated key production challenges, such as high manufacturing costs and frequent batch changeovers, thereby facilitating the expansion of contract manufacturing services worldwide.
Moreover, the market is experiencing a notable upsurge in demand due to a rise in strategic partnerships, mergers, and acquisitions among leading industry players. These collaborative efforts are reinforcing the global presence and capabilities of contract manufacturing organizations, contributing significantly to market growth.
List of Prominent Players in the Biotechnology Contract Manufacturing Market:
• Lonza (Switzerland)
• Samsung Biologics (South Korea)
• Thermo Fisher Scientific, Inc. (US)
• Catalent, Inc. (US)
• JSR Corporation (Japan)
• WuXi Biologics (China)
• AbbVie, Inc. (US)
• Boehringer Ingelheim International GmbH (Germany)
• Eurofins Scientific (Luxembourg)
• GenScript Biotech Corporation (US)
• AGC, Inc. (Japan)
• FUJIFILM Holding Corporation (Japan)
• Merck KgaA (Germany)
• Stelis
• Recipharm Ab
• Emergent
• Shanghai Fosun Pharmaceutical Co., Ltd.
• Lotte Biologics
• Hepalink Group
• Curia Global, Inc.
• Jrs Pharma
• Minapharm Pharmaceuticals
• Rentschler Biopharma Se
• Avid Bioservices, Inc.
• Abzena Ltd.
• Polyplus Transfection
• Midas Pharma Gmbh
• Mabplex International Co., Ltd.
• Asahi Kasei Corporation
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics
Drivers:
The global biotechnology contract manufacturing market is expected to witness robust growth over the forecast period, driven by several key factors. These include increasing investments in research and development, growing demand for generic pharmaceuticals, and the adoption of advanced manufacturing technologies. Additional growth drivers include the rising need for biological therapies, expansion in the nuclear medicine segment, and a heightened focus on specialty pharmaceuticals. Furthermore, increased scientific interest and innovation in the treatment of life-threatening diseases have significantly contributed to the recent growth of the biopharmaceutical contract manufacturing sector.
Challenges:
Despite the positive outlook, the market faces several challenges that may hinder its growth. These include operational complexities in the biopharmaceutical manufacturing process, such as issues related to labeling, packaging, and sterilization. Moreover, limited consumer awareness and lack of trust in outsourced manufacturing processes could pose additional barriers to market expansion during the forecast period.
Regional Trends:
The Asia Pacific region is poised for significant growth in the biotechnology contract manufacturing market. This is primarily attributed to rising investments in pharmaceutical R&D, an increasing trend toward outsourcing manufacturing services, and proactive government initiatives supporting healthcare research and innovation. Enhanced investment in healthcare infrastructure and research capabilities across the region is further accelerating market development.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2067
Recent Developments:
• In January 2023, GSK plc and WuXi Biologics have a licensing arrangement for using WuXi Biologics’ exclusive technological platforms. In accordance with this, GSK was given an exclusive worldwide license for the WuXi Biologics plan’s bispecific antibody research, development, production, and marketing.
• In May 2020, GSK formed a partnership with Samsung Biologics to secure additional manufacturing capacity for their innovative biopharmaceutical portfolio. Under the provisions of the agreement, Samsung Biologics provided GSK with additional biopharmaceutical product manufacturing capacity on a large scale. This capacity was adaptable to GSK’s future requirements and complemented the company’s existing manufacturing network.
Segmentation of Biotechnology Contract Manufacturing Market-
By Service
• Manufacturing
• Formulation and Fill-Finish
• Packaging and Labeling
• Other services
By Type
• Biologic Drug Substance Manufacturing
• Biologic Drug Product Manufacturing
By Scale of Operation
• Commercial Operations
• Clinical Operations
By Source
• Mammalian Expression Systems
• Non-Mammalian Expression Systems
By Molecule
• Monoclonal Antibodies
• Cell Therapy & Gene Therapy
• Antibody-Drug Conjugates (ADCs)
• Vaccines
• Therapeutic Peptides & Proteins
• Other Molecule Types
By Therapeutic Area
• Oncology
• Autoimmune Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Infectious Diseases
• Neurology
• Other Therapeutic Areas
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/biotechnology-contract-manufacturing-market/2067
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.